Center for Applied Proteomics and Molecular Medicine

Center for Applied Proteomics and Molecular Medicine

Co-Directors, Lance A. Liotta and Emanuel Petricoin III

Acronym: CAPMM Website
Unit: College of Science (COS)
Department: School for Systems Biology (SSB) Phone: 703) 993-9526
Fax: (703) 993-8606
Location: 10900 University Blvd. Bull Run Hall Room 325, MS1A9 Manassas, Virginia 20110

CAPMM'S mission is to: a) create new technologies and make basic science discoveries in the field of disease pathogenesis b) apply these discoveries and technologies to create and implement strategies for disease prevention, early diagnosis and individualized therapY.


The Center for Applied Proteomics and Molecular Medicine (CAPMM) was founded at George Mason University in 2005 and is co-directed by Lance Liotta, MD, PhD and Emanuel Petricoin III, PhD, innovators in the field of proteomics and personalized medicine. We are an academic research center within the College of Science, School of Systems Biology on the Prince William campus of George Mason University. Our biomedical research team consists of 15 scientists and 9 fellows from varied backgrounds and disciplines including medicine, biology, chemical and biomedical engineering, medical technology, and mathematics. Our research team strives to transform medical research through bench-to-bedside translational research in a variety of diseases including cancer (multiple myeloma, breast, brain, prostate, lung, ovarian skin and colorectal), neurodegenerative disease such as Alzheimer’s disease, traumatic brain injury, cardiovascular disease, liver and obesity disorders and infectious disease including sepsis and Lyme disease. CAPMM collaborates with regional, national and international scientists and physicians to design and implement innovative clinical research trials and diagnostic tests that may pave the way to earlier diagnosis, and individualized treatment of specific types of cancer and other diseases.

Since our inception in 2005, the Center has generated 132 publications and 44 patent applications in the areas of cancer, nanotechnology, liver disease, Alzheimer’s disease, infectious disease, cardiovascular diseases and medical technologies. In addition, two biotechnology companies, Ceres Nanosciences, Inc. and Theranostics Health, Inc. have been founded based on CAPMM-developed technologies and related discoveries.

Skip to toolbar